Live Earnings Conference Call: Neurocrine Biosciences will host a live Q1 2026 earnings call on May 5, 2026 at 4:30PM ET. Get details.

Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

$134.01 -0.06 (-0.04%)

As of 03:51 PM Eastern

Compare

Neurocrine Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 22 Analyst Ratings

Sell
0

Hold
5

Buy
17

Based on 22 Wall Street analysts who have issued ratings for Neurocrine Biosciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 5 have given a hold rating, 16 have given a buy rating, and 1 has given a strong buy rating for NBIX.

Consensus Price Target

$180.45
34.65% Upside

According to the 22 analysts' twelve-month price targets for Neurocrine Biosciences, the average price target is $180.45. The highest price target for NBIX is $242.00, while the lowest price target for NBIX is $140.00. The average price target represents a forecasted upside of 34.65% from the current price of $134.01.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for NBIX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Neurocrine Biosciences and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NBIX Analyst Ratings Over Time

Type	Current Forecast 5/5/25 to 5/5/26	1 Month Ago 4/5/25 to 4/5/26	3 Months Ago 2/4/25 to 2/4/26	1 Year Ago 5/5/24 to 5/5/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	16 Buy rating(s)	17 Buy rating(s)	19 Buy rating(s)
Hold	5 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$180.45	$175.10	$174.25	$160.90
Forecasted Upside	34.65% Upside	33.05% Upside	26.40% Upside	46.61% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

NBIX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NBIX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Neurocrine Biosciences Stock vs. The Competition

Type	Neurocrine Biosciences	Medical Companies	S&P 500
Consensus Rating Score	2.82	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	35.42% Upside	887.21% Upside	14.75% Upside
News Sentiment Rating	Positive News See Recent NBIX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
4/22/2026	Leerink Partners 2 of 5 stars	Marc Goodman Not Rated	Boost Target	Outperform	$160.00 ➝ $170.00	+30.01%
4/21/2026	Weiss Ratings Not Rated		Reiterated Rating	Hold (C+)
4/15/2026	Zacks Research Not Rated		Upgrade	Strong Sell ➝ Hold
4/10/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeffrey Hung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$173.00 ➝ $185.00	+42.41%
4/7/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yigal Nochomovitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$204.00 ➝ $242.00	+84.61%
4/7/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sumant Kulkarni Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$164.00 ➝ $200.00	+54.14%
4/7/2026	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Chico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$151.00 ➝ $166.00	+25.30%
4/7/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew S. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$192.00 ➝ $215.00	+62.29%
4/6/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ami Fadia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$185.00	+38.78%
3/12/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anupam Rama Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$176.00 ➝ $177.00	+37.76%

2/24/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rudy Li Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$160.00	+24.63%
2/17/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$169.00 ➝ $140.00	+8.14%
2/13/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$180.00 ➝ $175.00	+38.88%
2/12/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$180.00 ➝ $177.00	+40.46%
2/12/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Perform	$147.00 ➝ $140.00	+11.21%
1/23/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ashwani Verma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$188.00 ➝ $178.00	+29.54%
12/12/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Uy Ear Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$146.00 ➝ $175.00	+13.68%
12/11/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$183.00 ➝ $188.00	+20.80%
12/5/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Phil Nadeau Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$175.00 ➝ $200.00	+27.73%
10/29/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Amsellem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$175.00 ➝ $179.00	+28.64%
8/1/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yatin Suneja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$165.00 ➝ $175.00	+38.86%
7/10/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Corinne Johnson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$182.00	+36.32%
4/24/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cory Kasimov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$190.00 ➝ $185.00	+81.67%
2/11/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Hold	$138.00	+16.15%
2/7/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
2/7/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$184.00 ➝ $179.00	+18.93%
12/23/2024	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Overweight	$160.00 ➝ $165.00	+21.84%
10/10/2024	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$155.00	+38.86%
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$155.00 ➝ $155.00	+26.85%
8/19/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$177.00 ➝ $189.00	+29.88%
8/2/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$216.00 ➝ $219.00	+44.21%
8/2/2024	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$157.00 ➝ $180.00	+15.96%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:52 PM ET.

NBIX Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Neurocrine Biosciences is $180.45, with a high forecast of $242.00 and a low forecast of $140.00.
: 22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 5 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NBIX shares.
: According to analysts, Neurocrine Biosciences's stock has a predicted upside of 34.65% based on their 12-month stock forecasts.
: Over the previous 90 days, Neurocrine Biosciences's stock had 2 upgrades and 1 downgrade by analysts.
: Neurocrine Biosciences has been rated by research analysts at BMO Capital Markets, Canaccord Genuity Group, Citigroup, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Needham & Company LLC, Royal Bank Of Canada, Truist Financial, Wedbush, Weiss Ratings, Wells Fargo & Company, Wolfe Research, and Zacks Research in the past 90 days.
: Analysts like Neurocrine Biosciences more than other "medical" companies. The consensus rating for Neurocrine Biosciences is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how NBIX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Neurocrine Biosciences Recommendations

This page (NASDAQ:NBIX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

NBIX Analyst Ratings Over Time

NBIX Analyst Recommendations By Month

NBIX Price Targets by Month

Neurocrine Biosciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

NBIX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Neurocrine Biosciences Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

NBIX Analyst Ratings Over Time

NBIX Analyst Recommendations By Month

NBIX Price Targets by Month

Neurocrine Biosciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

NBIX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Neurocrine Biosciences Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools